Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 52-Week Low - Should You Sell?

Key Points

• Alnylam Pharmaceuticals shares hit a new 52-week low, falling to $179.87 from a prior close of $232.40, with the stock trading below both its 50-day and 200-day moving averages.
• Despite the decline, analysts maintain a consensus “Moderate Buy” rating with a $364.95 price target; ratings include 3 Strong Buys, 16 Buys, and 7 Holds.
• The company reported a strong quarter, posting $16.26 in EPS versus a $1.66 estimate and $1.46 billion in revenue, up 16.7% year over year. Institutional investors own 92.97% of the shares, while insider ownership is 0.86%.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Thursday. The stock traded as low as $179.87 and last traded at $195.2640, with a volume of 671,226 shares traded. The stock had previously closed at $232.40.

Analyst Upgrades and Downgrades

Several analysts have commented on ALNY shares. Citigroup reduced their price objective on Alnylam Pharmaceuticals from $340.00 to $320.00 and set a "buy" rating for the company in a research note on Wednesday, October 14th. Jefferies Financial Group boosted their target price on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a "hold" rating in a report on Tuesday, September 8th. Oppenheimer reduced their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an "outperform" rating for the company in a research note on Friday, July 31st. Zacks Research downgraded shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, October 23rd. Finally, TD Cowen reiterated a "buy" rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $364.95.

Alnylam Pharmaceuticals Stock Performance

The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $25.24 billion, a PE ratio of 35.27 and a beta of 0.28. The stock's fifty day simple moving average is $239.15 and its 200-day simple moving average is $288.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating the consensus estimate of $1.66 by $14.60. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. Alnylam Pharmaceuticals's quarterly revenue was up 16.7% on a year-over-year basis. During the same period last year, the business posted $2.90 EPS. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Bryan Supran sold 1,758 shares of the business's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. The trade was a 12.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Toth Financial Advisory Corp bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $25,000. Keating Financial Advisory Services Inc. acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $42,000. Burkett Financial Services LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $37,000. CoreCap Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 744.4% during the third quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 134 shares during the last quarter. Finally, Ascentis Independent Advisors acquired a new position in Alnylam Pharmaceuticals in the first quarter worth approximately $64,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company's therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam's marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.